Free Trial
NASDAQ:RXRX

Recursion Pharmaceuticals Q3 2024 Earnings Report

Recursion Pharmaceuticals logo
$4.74 -0.13 (-2.57%)
As of 12:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recursion Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.01
One Year Ago EPS
-$0.43

Recursion Pharmaceuticals Revenue Results

Actual Revenue
$26.08 million
Expected Revenue
$12.62 million
Beat/Miss
Beat by +$13.46 million
YoY Revenue Growth
+147.60%

Recursion Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Recursion Pharmaceuticals' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Recursion Pharmaceuticals Earnings Headlines

Recursion to Participate in Upcoming Investor Conferences
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
See More Recursion Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Recursion Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your email.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals (NASDAQ:RXRX) operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Recursion Pharmaceuticals Profile

More Earnings Resources from MarketBeat